Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions

[1]  J. Becker,et al.  B-Raf specific antibody responses in melanoma patients , 2004, BMC Cancer.

[2]  John Calvin Reed,et al.  HBXIP functions as a cofactor of survivin in apoptosis suppression , 2003, The EMBO journal.

[3]  B. Bastian.  Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer , 2003, Oncogene.

[4]  H. Stein,et al.  Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma , 2003, British Journal of Cancer.

[5]  D. Grossman,et al.  Apoptosis regulators and responses in human melanocytic and keratinocytic cells. , 2003, The Journal of investigative dermatology.

[6]  S. Fukuda,et al.  The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. , 2002, Blood.

[7]  D. Altieri,et al.  A p34(cdc2) survival checkpoint in cancer. , 2002, Cancer cell.

[8]  K. Shroyer,et al.  Immunohistochemical localization of survivin in benign cervical mucosa, cervical dysplasia, and invasive squamous cell carcinoma. , 2002, American journal of clinical pathology.

[9]  T. Giordano,et al.  Survivin: a novel neuroendocrine marker for pheochromocytoma. , 2002, European journal of endocrinology.

[10]  Jian J Lu,et al.  Tumor necrosis factor-α induces the expression of DR6, a member of the TNF receptor family, through activation of NF-κB , 2001, Oncogene.

[11]  O. Ishiko,et al.  Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. , 2001, International journal of oncology.

[12]  J. Darnell,et al.  Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Y. Takano,et al.  Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. , 2001, Cancer letters.

[14]  W. Gerald,et al.  Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001, Nature.

[15]  W. Sessa.  No longer a molecular black box - new clues to apoptosis and drug resistance in melanoma , 2001 .

[16]  J. Lu,et al.  Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB. , 2001, Oncogene.

[17]  J. Downward,et al.  The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. , 2000, Journal of cell science.

[18]  G. Salvesen,et al.  ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas , 2000, Current Biology.

[19]  J Diebold,et al.  Prognostic significance of survivin expression in diffuse large B-cell lymphomas. , 2000, Blood.

[20]  C. Berking,et al.  Lessons from melanocyte development for understanding the biological events in naevus and melanoma formation , 2000, Melanoma research.

[21]  K. Shiraki,et al.  Survivin promotes cell proliferation in human hepatocellular carcinoma , 2000, Hepatology.

[22]  M. Herlyn,et al.  Dynamics of intercellular communication during melanoma development. , 2000, Molecular medicine today.

[23]  C. Badie,et al.  Repression of CDK1 and Other Genes with CDE and CHR Promoter Elements during DNA Damage-Induced G2/M Arrest in Human Cells , 2000, Molecular and Cellular Biology.

[24]  M. Tucker,et al.  Lack of germline CDK6 mutations in familial melanoma , 2000, Oncogene.

[25]  M. Ohira,et al.  High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma , 2000, Oncogene.

[26]  J. McNiff,et al.  Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. , 1999, The Journal of investigative dermatology.

[27]  J. McNiff,et al.  Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[28]  R. Weiss,et al.  Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. , 1999, New England Journal of Medicine.

[29]  T. Alanko,et al.  FGF expression allows nevus cells to survive in three-dimensional collagen gel under conditions that induce apoptosis in normal human melanocytes. , 1999, The Journal of investigative dermatology.

[30]  B. Gilchrest,et al.  The pathogenesis of melanoma induced by ultraviolet radiation. , 1999, The New England journal of medicine.

[31]  U. Brinkmann,et al.  Expression of the proliferation and apoptosis-associated CAS protein in benign and malignant cutaneous melanocytic lesions. , 1999, The American Journal of dermatopathology.

[32]  R. Bergman,et al.  Apoptosis, Fas and Fas‐ligand expression in melanocytic tumors , 1999, Journal of cutaneous pathology.

[33]  F. Marincola,et al.  Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. , 1998, Journal of immunology.

[34]  M. Herlyn,et al.  Molecular events in melanoma development and progression. , 1998, Frontiers in bioscience : a journal and virtual library.

[35]  P. Hersey,et al.  TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. , 1998, Journal of immunology.

[36]  J. Reed,et al.  Expression of apoptosis regulators in cutaneous malignant melanoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  G. Sirugo,et al.  Induction of Apoptosis and Inhibition of Cell Proliferation bysurvivin Gene Targeting* , 1998, The Journal of Biological Chemistry.

[38]  V. Tron,et al.  Chemotherapy-induced apoptosis in melanoma cells is p53 dependent , 1998, Melanoma research.

[39]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[40]  M. van de Rijn,et al.  bcl-2 expression in melanocytic nevi. Insights into the biology of dermal maturation. , 1995, Archives of dermatology.

[41]  E. Mooney,et al.  Apoptotic and mitotic indices in malignant melanoma and basal cell carcinoma. , 1995, Journal of clinical pathology.

[42]  Gwyn T. Williams,et al.  Molecular regulation of apoptosis: Genetic controls on cell death , 1993, Cell.

[43]  M. Raff,et al.  Social controls on cell survival and cell death , 1992, Nature.

[44]  Gwyn T. Williams.  Programmed cell death: Apoptosis and oncogenesis , 1991, Cell.